Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies

被引：31

作者：

Cartin-Ceba, Rodrigo ^{[1
]}

Halank, Michael ^{[2
]}

Ghofrani, Hossein-Ardeschir ^{[3
,4
]}

Humbert, Marc ^{[5
,6
,7
]}

Mattson, John ^{[8
]}

Fritsch, Arno ^{[9
]}

Krowka, Michael J. ^{[10
]}

机构：

[1] Mayo Clin, Div Pulm Med, Dept Med, Scottsdale, AZ USA

[2] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Internal Med 1, Dresden, Germany

[3] UGMLC, German Ctr Lung Res DZL, Giessen, Germany

[4] Imperial Coll London, Dept Med, London, England

[5] Univ Paris Sud, Univ Paris Saclay, Le Kremlin Bicetre, France

[6] Hop Bicetre, AP HP, Serv Pneumol, Le Kremlin Bicetre, France

[7] Hop Marie Lannelongue, Inst Natl Sante & Rech Med UMR S999, Le Plessis Robinson, France

[8] Bayer US LLC, Med Affairs, Whippany, NJ USA

[9] Bayer AG, Pharmaceut Stat, Wuppertal, Germany

[10] Mayo Clin, Transplant Ctr, Rochester, MN USA

来源：

PULMONARY CIRCULATION | 2018年 / 8卷 / 02期

关键词：

soluble guanylate cyclase stimulator; portal hypertension; pulmonary arterial hypertension; PULMONARY ARTERIAL-HYPERTENSION; DISEASE; GUIDELINES; MANAGEMENT; EXTENSION; DIAGNOSIS; REGISTRY; REVEAL;

D O I：

10.1177/2045894018769305

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In patients with portopulmonary hypertension (n=13) included in the 12-week randomized placebo-controlled PATENT-I trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.

引用

页数：4

共 20 条

[1]

Bayer AG, Adempas US prescribing information

[2] Predicting Survival in Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) [J].

Benza, Raymond L. ;

Miller, Dave P. ;

Gomberg-Maitland, Mardi ;

Frantz, Robert P. ;

Foreman, Aimee J. ;

Coffey, Christopher S. ;

Frost, Adaani ;

Barst, Robyn J. ;

Badesch, David B. ;

Elliott, C. Gregory ;

Liou, Theodore G. ;

McGoon, Michael D. .

CIRCULATION, 2010, 122 (02) :164-U138

[3] What's new in the treatment of portopulmonary hypertension? [J].

DuBrock, Hilary M. ;

Channick, Richard N. ;

Krowka, Michael J. .

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 9 (07) :983-992

[4]

Eriksson C, 2011, J GASTROINTEST LIVER, V20, P77

[5] Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521) [J].

Frey, Reiner ;

Becker, Corina ;

Unger, Sigrun ;

Schmidt, Anja ;

Wensing, Georg ;

Mueck, Wolfgang .

PULMONARY CIRCULATION, 2016, 6 :S5-S14

[6] Comparison of hemodynamic parameters in treatment-naive and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study [J].

Gabe, Nazzareno ;

Grimminger, Friedrich ;

Gruenig, Ekkehard ;

Hoeper, Marius M. ;

Humbert, Marc ;

Jing, Zhi-Cheng ;

Keogh, Anne M. ;

Langleben, David ;

Rubin, Lewis J. ;

Fritsch, Arno ;

Davie, Neil ;

Ghofrani, Hossein-Ardeschir .

JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (05) :509-519

[7] 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension [J].

Galie, Nazzareno ;

Humbert, Marc ;

Vachiery, Jean-Luc ;

Gibbs, Simon ;

Lang, Irene ;

Torbicki, Adam ;

Simonneau, Gerald ;

Peacock, Andrew ;

Noordegraaf, Anton Vonk ;

Beghetti, Maurice ;

Ghofrani, Ardeschir ;

Sanchez, Miguel Angel Gomez ;

Hansmann, Georg ;

Klepetko, Walter ;

Lancellotti, Patrizio ;

Matucci, Marco ;

McDonagh, Theresa ;

Pierard, Luc A. ;

Trindade, Pedro T. ;

Zompatori, Maurizio ;

Hoeper, Marius .

EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (04) :903-975

[8] PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension [J].

Galie, Nazzareno ;

Mueller, Katharina ;

Scalise, Andrea-Viviana ;

Gruenig, Ekkehard .

EUROPEAN RESPIRATORY JOURNAL, 2015, 45 (05) :1314-1322

[9] Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial [J].

Ghofrani, Hossein-Ardeschir ;

Grimminger, Friedrich ;

Gruenig, Ekkehard ;

Huang, Yigao ;

Jansa, Pavel ;

Jing, Zhi-Cheng ;

Kilpatrick, David ;

Langleben, David ;

Rosenkranz, Stephan ;

Menezes, Flavia ;

Fritsch, Arno ;

Nikkho, Sylvia ;

Humbert, Marc .

LANCET RESPIRATORY MEDICINE, 2016, 4 (05) :361-371

[10] Riociguat for the Treatment of Pulmonary Arterial Hypertension [J].

Ghofrani, Hossein-Ardeschir ;

Galie, Nazzareno ;

Grimminger, Friedrich ;

Gruenig, Ekkehard ;

Humbert, Marc ;

Jing, Zhi-Cheng ;

Keogh, Anne M. ;

Langleben, David ;

Kilama, Michael Ochan ;

Fritsch, Arno ;

Neuser, Dieter ;

Rubin, Lewis J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (04) :330-340

← 1 2 →